Primary Gastric Lymphoma : Conservative Treatment Modality Is Not Inferior to Surgery for Early-Stage Disease

Abstract EN

Objectives.

The aim of this study was to evaluate clinical characteristics, prognostic factors, survival rates, and treatment modalities in patients with primary gastric lymphoma (PGL).

Methods.

We retrospectively reviewed and analyzed data from patients treated for PGL in our clinic from 1998 through 2010.

Staging was performed using the Lugano Staging System.

Overall and disease-free survival (OS and DFS) were calculated from the date of diagnosis.

Results.

We identified 79 patients.

Thirty-seven patients (47%) were male.

The median age at presentation was 57 (18–85) years.

The median follow-up time was 41 (9–52) months.

Thirty patients (38%) underwent surgery, 74 (92%) received chemotherapy, and 18 (23%) received radiotherapy.

The five-year OS and DFS rates were 91.2% and 83.9%, respectively, in patients with stage I/II or IIE disease and 70.6% and 65.5%, respectively, in patients with stage IV disease (P=0.02 for both rates).

Treatment modality (surgical or conservative) had no impact on OS or DFS in early stages.

In a multivariate analysis, poor performance status, advanced stage, and high LDH levels were significant bad prognostic factors for DFS, while advanced stage, poor performance status, and age > 60 years were significant bad prognostic factors for OS.

Conclusion.

Surgery provides no advantage for survival over conservative treatment; thus, conservative treatment modalities should be preferred initially at early stages of PGL.